• Aclarion highlighted new NIH-funded research using its Nociscan MRS platform in Modic type 1 back-pain patients; results have already been presented.
• The study linked a disc-derived biochemical signal to a distinct immune-activation subtype, supporting a non-structural driver of pain in some patients.
• The findings broaden Nociscan’s strategic positioning beyond surgical decision support into patient stratification for inflammation, infection-related processes, or immune-associated pain.
• This could expand the addressable market by guiding future personalized therapy development, including anti-inflammatory, antimicrobial, or immune-modulating approaches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010600PRIMZONEFULLFEED9729186) on June 01, 2026, and is solely responsible for the information contained therein.